327 related articles for article (PubMed ID: 25947625)
1. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
Mancuso R; Hernis A; Agostini S; Rovaris M; Caputo D; Clerici M
J Transl Med; 2015 May; 13():148. PubMed ID: 25947625
[TBL] [Abstract][Full Text] [Related]
2. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.
Samson RS; Cardoso MJ; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ron M; Ourselin S; Miller DH; Chard DT
Mult Scler; 2014 Sep; 20(10):1322-30. PubMed ID: 24552746
[TBL] [Abstract][Full Text] [Related]
3. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
[TBL] [Abstract][Full Text] [Related]
4. Analysis of potential microRNA biomarkers for multiple sclerosis.
Al-Temaimi R; Alshammari N; Alroughani R
Exp Mol Pathol; 2024 Jun; 137():104903. PubMed ID: 38772208
[TBL] [Abstract][Full Text] [Related]
5. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E
Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141
[No Abstract] [Full Text] [Related]
6. Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
Ruhrmann S; Ewing E; Piket E; Kular L; Cetrulo Lorenzi JC; Fernandes SJ; Morikawa H; Aeinehband S; Sayols-Baixeras S; Aslibekyan S; Absher DM; Arnett DK; Tegner J; Gomez-Cabrero D; Piehl F; Jagodic M
Mult Scler; 2018 Sep; 24(10):1288-1300. PubMed ID: 28766461
[TBL] [Abstract][Full Text] [Related]
7. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
[TBL] [Abstract][Full Text] [Related]
9. SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
Malhotra S; Castilló J; Bustamante M; Vidal-Jordana A; Castro Z; Montalban X; Comabella M
Mult Scler; 2013 Apr; 19(5):524-31. PubMed ID: 22933622
[TBL] [Abstract][Full Text] [Related]
10. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
[TBL] [Abstract][Full Text] [Related]
11. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
Fenoglio C; Ridolfi E; Cantoni C; De Riz M; Bonsi R; Serpente M; Villa C; Pietroboni AM; Naismith RT; Alvarez E; Parks BJ; Bresolin N; Cross AH; Piccio LM; Galimberti D; Scarpini E
Mult Scler; 2013 Dec; 19(14):1938-42. PubMed ID: 24277735
[TBL] [Abstract][Full Text] [Related]
12. Decreased MMP-9 production in primary progressive multiple sclerosis patients.
Sastre-Garriga J; Comabella M; Brieva L; Rovira A; Tintoré M; Montalban X
Mult Scler; 2004 Aug; 10(4):376-80. PubMed ID: 15327032
[TBL] [Abstract][Full Text] [Related]
13. Exosomal microRNA signatures in multiple sclerosis reflect disease status.
Ebrahimkhani S; Vafaee F; Young PE; Hur SSJ; Hawke S; Devenney E; Beadnall H; Barnett MH; Suter CM; Buckland ME
Sci Rep; 2017 Oct; 7(1):14293. PubMed ID: 29084979
[TBL] [Abstract][Full Text] [Related]
14. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
Kacperska MJ; Jastrzebski K; Tomasik B; Walenczak J; Konarska-Krol M; Glabinski A
J Mol Neurosci; 2015 May; 56(1):154-63. PubMed ID: 25487315
[TBL] [Abstract][Full Text] [Related]
15. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
[TBL] [Abstract][Full Text] [Related]
16. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
[TBL] [Abstract][Full Text] [Related]
17. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.
Silversides JA; Heggarty SV; McDonnell GV; Hawkins SA; Graham CA
Mult Scler; 2004 Apr; 10(2):149-52. PubMed ID: 15124759
[TBL] [Abstract][Full Text] [Related]
18. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
[TBL] [Abstract][Full Text] [Related]
19. Circulating microRNAs as biomarkers in progressive multiple sclerosis.
Vistbakka J; Elovaara I; Lehtimäki T; Hagman S
Mult Scler; 2017 Mar; 23(3):403-412. PubMed ID: 27246141
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-125a-5p and miR-218-5p in Peripheral Blood Mononuclear Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
Mosarrezaii Aghdam A; Rezaei S; Zarza Nalivan F; Babaie F; Amiri Nikpour MR; Torkamandi S
Immunol Invest; 2022 Jul; 51(5):1149-1161. PubMed ID: 33866949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
